The Great CDMO Constriction: Why Time, Not Capacity, Is Now Breaking the CDMO System
Capacity is no longer what limits pharmaceutical manufacturing. This briefing argues the binding constraint has become time: the months lost to utility limits, regulatory holds, tech-transfer friction and block-booked slots. It sets out where that constriction forms, what it does to funded biotechs, and which operating models are unlikely to survive it.
What this report answers
- Why can procurement teams not book a fill-finish slot when global bioreactor volume is still growing?
- What separates a facility that has opened from a facility that can actually ship commercial product?
- How long does it really take to move a programme out of China, and what drives that delay?
- What happens to a Series B company when manufacturing takes eighteen months instead of six?
- Who still has access to the merchant CDMO market now that the largest sponsors have block-booked it?
- When does the market normalise, and what does it look like on the other side?
$480bn+
committed to domestic manufacturing investment between 2021 and 2024 - the capital the briefing argues has been misread as the bottleneck being solved.
73%
the surge in FDA Warning Letters in the first half of FY2025 that the briefing attributes to a change in how inspection risk is targeted.
What the analysis establishes
Built is not the same as runnable
The briefing separates mechanical completion from commercial readiness and works through what sits in the gap. It establishes that some of the constraint is mundane and physical, tied to municipal infrastructure and permitting timelines rather than to steel, and that another part is regulatory. Named facilities on both sides of that split are used as worked case studies.
How inspection risk is now targeted
A section on the enforcement environment sets out how regulatory attention is allocated differently than it was, what that has done to the volume and pattern of citations, and how it interacts with a workforce diluted by rapid expansion. It also describes the knock-on effect on mutual recognition between US and European regulators.
The friction cost of decoupling
Exiting China is examined as a scientific reconstruction rather than a change of address. The briefing quantifies the delay it attaches to those transfers and traces it to specific technical divergences in materials and analytics, explaining the mechanism by which each one forces work to be redone rather than simply relocated.
The end of the merchant market
The briefing documents how the largest sponsors have moved from renting capacity to enclosing it, through outright acquisition, dedicated-capacity agreements and ecosystem-level booking. It also covers a quieter structural subtraction: how suites converted for one modality rarely return to general use, and what that removes from everyone else.
What the constriction does to a company
A failure mode the briefing calls operational bankruptcy is set out in detail: solvent on paper, out of time in practice. It walks through how delay consumes a financing round, cites companies whose recent difficulties fit the pattern, and describes how investors are repricing programmes whose readouts have moved.
The three-horizon response
The closing part gives recommendations split across survival, tactical positioning and structural resilience horizons. It covers supply-chain auditing, how to think about process design under slot scarcity, where to look for less saturated Western-aligned capacity, and what a sponsor should own rather than outsource.
How it was built
Written as a forensic read of the operating environment rather than a market sizing. It combines publicly available information, anonymised market signals and aggregated observations from ProGen Search's active search and advisory engagements across CDMO, pharma and biotech. Individual facilities, permits and inspection outcomes are used as worked evidence. Where the report gives a share of announced capacity it believes is dormant, it labels that as its own estimate rather than a measured figure, and it presents its numbers as directional intelligence for the 2026 to 2028 planning horizon. It follows an earlier ProGen report, The CDMO Reckoning.
Written for CDMO boards and executive teams, private equity sponsors, and biotech leadership and investors making outsourcing, capital allocation and organisational design decisions under execution risk.
Contents
- Executive Preamble: The End of the Rental Market
- Part I: The Problems Staring Us in the Face
- The Ghost Capacity Phenomenon
- The Weaponisation of Regulatory Data
- The Time Tax of Decoupling
- Strategic Enclosure: The Death of the Spot Market
- Part II: The Impact - short, medium and long term
- Part III: Strategic Recommendations
Organisations and regulators referenced
Amgen, Areteia Therapeutics, BestChrom, Cambrex, Catalent, CSL Seqirus, Cygnus, Cytiva, Eli Lilly, EMA, FDA, Fujifilm Diosynth Biotechnologies, LePure, Lonza, Mythic Therapeutics, NanoMicro, Nexus Pharmaceuticals, Novo Holdings, Novo Nordisk, Rocket Pharmaceuticals, Samsung Biologics, Sanofi, Texcell, Ultragenyx, WuXi
The full 11-page briefing is free. Tell us where to send it and it downloads immediately.
Weaponised Capacity: The CDMO Report 2026
The flagship CDMO report is the paid companion to this briefing: full sector structure, named operators, and where schedulable Western capacity actually sits.
See the full report →